Leerink Partnrs Predicts REGENXBIO FY2029 Earnings

REGENXBIO Inc. (NASDAQ:RGNX) – Research analysts at Leerink Partnrs issued their FY2029 EPS estimates for REGENXBIO in a report issued on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar anticipates that the biotechnology company will earn $0.46 per share for the year. The consensus estimate for REGENXBIO’s current full-year earnings is ($4.87) per share.

A number of other research analysts have also recently commented on the stock. HC Wainwright reissued a “buy” rating and issued a $36.00 target price on shares of REGENXBIO in a report on Wednesday, January 15th. Chardan Capital reiterated a “buy” rating and issued a $52.00 price objective on shares of REGENXBIO in a report on Wednesday, November 20th. Raymond James reiterated an “outperform” rating and issued a $18.00 price objective on shares of REGENXBIO in a report on Thursday, October 10th. Morgan Stanley reiterated an “overweight” rating and issued a $22.00 price objective on shares of REGENXBIO in a report on Friday, November 15th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $30.00 price objective on shares of REGENXBIO in a report on Tuesday. One research analyst has rated the stock with a sell rating, one has given a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $34.82.

REGENXBIO Trading Down 0.9 %

RGNX stock opened at $7.88 on Thursday. The stock has a market capitalization of $390.38 million, a P/E ratio of -1.57 and a beta of 1.28. REGENXBIO has a 12 month low of $6.56 and a 12 month high of $28.80. The firm has a 50-day moving average price of $8.42 and a 200-day moving average price of $10.38.

Institutional Trading of REGENXBIO

Several large investors have recently modified their holdings of the stock. Redmile Group LLC grew its position in shares of REGENXBIO by 7.1% during the 3rd quarter. Redmile Group LLC now owns 4,892,902 shares of the biotechnology company’s stock worth $51,327,000 after buying an additional 323,100 shares during the period. Geode Capital Management LLC grew its position in shares of REGENXBIO by 4.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,088,651 shares of the biotechnology company’s stock worth $11,422,000 after buying an additional 44,037 shares during the period. Assenagon Asset Management S.A. grew its position in shares of REGENXBIO by 53.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company’s stock worth $6,621,000 after buying an additional 296,700 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of REGENXBIO by 9.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 417,739 shares of the biotechnology company’s stock worth $4,382,000 after purchasing an additional 37,055 shares in the last quarter. Finally, Millennium Management LLC lifted its holdings in shares of REGENXBIO by 84.8% in the 2nd quarter. Millennium Management LLC now owns 306,487 shares of the biotechnology company’s stock worth $3,586,000 after purchasing an additional 140,666 shares in the last quarter. Institutional investors and hedge funds own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.